Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist

• Published in: The Annals of pharmacotherapy Vol. 44; no. 3; p. 524
• Main Authors: Anderson, Shawn D, Shah, Niren K, Yim, Juwon, Epstein, Benjamin J
• Format: Journal Article
• Language: English
• Published: United States 01.03.2010
• Subjects: Acute Coronary Syndrome - complications; Acute Coronary Syndrome - drug therapy; Acute Coronary Syndrome - physiopathology; Adenosine - adverse effects; Adenosine - analogs & derivatives; Adenosine - pharmacology; Adenosine - therapeutic use; Animals; Cardiovascular Diseases - etiology; Cardiovascular Diseases - prevention & control; Humans; Platelet Aggregation Inhibitors - adverse effects; Platelet Aggregation Inhibitors - pharmacology; Platelet Aggregation Inhibitors - therapeutic use; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Ticlopidine - adverse effects; Ticlopidine - analogs & derivatives; Ticlopidine - therapeutic use

To summarize the pharmacokinetic and pharmacodynamic properties of ticagrelor, a selective P2Y12 receptor antagonist, and evaluate its role in the treatment of patients with acute coronary syndromes (ACS). A literature search was conducted in MEDLINE (1966-November 2009), International Pharmaceutica...